Aakaar Medical Technologies Limited — Investor Meet, 22-06-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Aakaar Medical reported FY26 revenue of 67 Cr (up 8.6% YoY), EBITDA of 11 Cr (up 12% YoY, 16.39% margin), and PAT of 6.63 Cr (up 10% YoY, 9.86% margin). H2 FY26 saw a strong rebound, turning an H1 loss into a 7.4 Cr PAT, driven by a strategic shift to cash-first billing, which cut debtor days from 209 to 167. The company expanded its customer base to over 6,300+ and launched new products like LETYBO. Aakaar is also building Xelix, a Doctor-Owned, Doctor-Operated (DODO) aesthetics platform, leveraging its vast doctor network and B2B supply chain for market leadership.